English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/191691
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorPalacios-Baena, Zaira Raqueles_ES
dc.contributor.authorGutiérrez-Gutiérrez, Belénes_ES
dc.contributor.authorCueto, Marina dees_ES
dc.contributor.authorViale, Pierluigies_ES
dc.contributor.authorVenditti, Marioes_ES
dc.contributor.authorHernández, Aliciaes_ES
dc.contributor.authorOliver, Antonioes_ES
dc.contributor.authorMartínez-Martínez, Luises_ES
dc.contributor.authorCalbo, Estheres_ES
dc.contributor.authorPintado, Vicentees_ES
dc.contributor.authorGasch, Orioles_ES
dc.contributor.authorAlmirante, Benitoes_ES
dc.contributor.authorLepe, José A.es_ES
dc.contributor.authorPitout, Johannes_ES
dc.contributor.authorAkova, Murates_ES
dc.contributor.authorPeña, Carmenes_ES
dc.contributor.authorSchwaber, Mitchell J.es_ES
dc.contributor.authorTumbarello, Marioes_ES
dc.contributor.authorTacconelli, Evelinaes_ES
dc.contributor.authorOrigüen, Juliaes_ES
dc.contributor.authorPrim, Nuriaes_ES
dc.contributor.authorBou, Germánes_ES
dc.contributor.authorGiamarellou, Helenes_ES
dc.contributor.authorBermejo, Joaquínes_ES
dc.contributor.authorHamprecht, Axeles_ES
dc.contributor.authorPérez, Federicoes_ES
dc.contributor.authorAlmela, Maneles_ES
dc.contributor.authorLowman, Warrenes_ES
dc.contributor.authorHsueh, Po-Renes_ES
dc.contributor.authorNavarro-San Francisco, Carolinaes_ES
dc.contributor.authorTorre-Cisneros, Juliánes_ES
dc.contributor.authorCarmeli, Yehudaes_ES
dc.contributor.authorBonomo, Robert A.es_ES
dc.contributor.authorPaterson, David L.es_ES
dc.contributor.authorPascual, Álvaroes_ES
dc.contributor.authorRodríguez-Baño, Jesúses_ES
dc.identifier.citationJournal of Antimicrobial Chemotherapy 72(3): 906-913 (2017)es_ES
dc.description.abstract[Background] Bloodstream infections (BSIs) due to ESBL-producing Enterobacteriaceae (ESBL-E) are frequent yet outcome prediction rules for clinical use have not been developed. The objective was to define and validate a predictive risk score for 30 day mortality.es_ES
dc.description.abstract[Methods] A multinational retrospective cohort study including consecutive episodes of BSI due to ESBL-E was performed; cases were randomly assigned to a derivation cohort (DC) or a validation cohort (VC). The main outcome variable was all-cause 30 day mortality. A predictive score was developed using logistic regression coefficients for the DC, then tested in the VC.es_ES
dc.description.abstract[Results] The DC and VC included 622 and 328 episodes, respectively. The final multivariate logistic regression model for mortality in the DC included age >50 years (OR = 2.63; 95% CI: 1.18–5.85; 3 points), infection due to Klebsiella spp. (OR = 2.08; 95% CI: 1.21–3.58; 2 points), source other than urinary tract (OR = 3.6; 95% CI: 2.02–6.44; 3 points), fatal underlying disease (OR = 3.91; 95% CI: 2.24–6.80; 4 points), Pitt score >3 (OR = 3.04; 95 CI: 1.69–5.47; 3 points), severe sepsis or septic shock at presentation (OR = 4.8; 95% CI: 2.72–8.46; 4 points) and inappropriate early targeted therapy (OR = 2.47; 95% CI: 1.58–4.63; 2 points). The score showed an area under the receiver operating curve (AUROC) of 0.85 in the DC and 0.82 in the VC. Mortality rates for patients with scores of < 11 and ≥11 were 5.6% and 45.9%, respectively, in the DC, and 5.4% and 34.8% in the VC.es_ES
dc.description.abstract[Conclusions] We developed and validated an easy-to-collect predictive scoring model for all-cause 30 day mortality useful for identifying patients at high and low risk of mortality.es_ES
dc.description.sponsorshipThis study was funded by: the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III co-financed by the European Development Regional Fund ‘A way to achieve Europe’ ERDF, the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), FIS grant PI10/02021 and FIS grant PI14/01832. B. G. G., J. R. B., A. P. and Y. C. also received funds from the COMBACTE-CARE project, Innovative Medicines Initiative (IMI), the European Union’s Seventh Framework Programme (FP7/2007-2013) and in-kind contributions from EFPIA companies. R. A. B. was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program and the Geriatric Research Education and Clinical Center VISN 10 (VISN 10 GRECC), and the NIAID of the NIH under award numbers R01AI072219 and R01AI063517.es_ES
dc.publisherOxford University Presses_ES
dc.titleDevelopment and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceaees_ES
dc.description.peerreviewedPeer reviewedes_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderEuropean Commissiones_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderRed Española de Investigación en Patología Infecciosaes_ES
dc.contributor.funderEuropean Federation of Pharmaceutical Industries and Associationses_ES
dc.contributor.funderCuyahoga County Veterans Service Commission (US)es_ES
dc.contributor.funderGeriatric Research Education and Clinical Center (US)es_ES
dc.contributor.funderNational Institute of Allergy and Infectious Diseases (US)es_ES
oprm.item.hasRevisionno ko 0 false*
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.